

S2 Table. AGR3 expression and pathological features in IDC of grade I - II

| Pathological features | No. | AGR3 expression, n (%) | | r_s | p-value |
|--|-----|------------------------|-----------|--------|---------|
| | | Low | High | | |
| Age (yr) | | | | -0.099 | 0.105 |
| < 50 | 127 | 67 (52.8) | 60 (47.2) | | |
| ≥ 50 | 139 | 87 (62.6) | 52 (37.4) | | |
| Tumor size (cm) ^{a)} | | | | 0.035 | 0.647 |
| < 2 | 66 | 39 (59.1) | 27 (40.9) | | |
| 2-5 | 180 | 105 (58.3) | 75 (41.7) | | |
| > 5 | 17 | 8 (47.1) | 9 (52.9) | | |
| Lymph node metastases | | | | -0.029 | 0.756 |
| 0 | 93 | 52 (55.9) | 41 (44.1) | | |
| 1-3 | 80 | 48 (60.0) | 32 (40.0) | | |
| 4-9 | 40 | 21 (52.5) | 19 (47.5) | | |
| > 9 | 53 | 33 (62.3) | 20 (37.7) | | |
| Distant metastasis | | | | 0.089 | 0.149 |
| No | 226 | 135 (59.7) | 91 (40.3) | | |
| Yes | 40 | 19 (47.5) | 21 (52.5) | | |
| ER status ^{a)} | | | | 0.333 | < 0.001 |
| Negative | 89 | 72 (80.9) | 17 (19.1) | | |
| Positive | 176 | 81 (46.0) | 95 (54.0) | | |
| PR status ^{a)} | | | | 0.224 | < 0.001 |
| Negative | 87 | 64 (73.6) | 23 (26.4) | | |
| Positive | 178 | 89 (50.0) | 89 (50.0) | | |
| HER2 status ^{a)} | | | | -0.113 | 0.066 |
| - to + | 212 | 117 (55.2) | 95 (44.8) | | |
| ++ to +++ | 52 | 36 (69.2) | 16 (30.8) | | |
| Ki-67 status ^{a)} | | | | 0.014 | 0.823 |
| Negative | 79 | 47 (59.5) | 32 (40.5) | | |
| Positive | 181 | 105 (58.0) | 76 (42.0) | | |
| Recurrence or distant metastasis ^{a)} | | | | 0.220 | < 0.001 |
| No | 211 | 134 (63.5) | 77 (36.5) | | |
| Yes | 50 | 18 (36.0) | 32 (64.0) | | |

AGR3, anterior gradient 3; IDC, invasive ductal carcinoma; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2. ^{a)}Some missing data; p-value was calculated by Spearman's Rank-Correlation test.